The possible effects of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin H receptor blockers (ARBs) on COVID-19 disease severity have generated considerable debate.We performed a single-center,retrospective analysis of hospitalized adult COVID-19 patients in Wuhan,China,who had definite clinical outcome (dead or discharged) by February 15,2020.Patients on anti-hypertensive treatment with or without ACEI/ARB were compared on their clinical characteristics and outcomes.The medical records from 702 patients were screened.Among the 101 patients with a history of hypertension and taking at least one anti-hypertensive medication,40 patients were receiving ACEI/ARB as part of their regimen,and 61 patients were on anti-hypertensive medication other than ACEI/ARB.We observed no statistically significant differences in percentages of in-hospital mortality (28％ vs.34％,P =0.46),ICU admission (20％ vs.28％,P =0.37) or invasive mechanical ventilation (18％ vs.26％,P =0.31) between patients with or without ACEI/ARB treatment.Further multivariable adjustment of age and gender did not provide evidence for a significant association between ACEI/ARB treatment and severe COVID-19 outcomes.Our findings confirm the lack of an association between chronic receipt of renin-angiotensin system antagonists and severe outcomes of COVID-19.Patients should continue previous anti-hypertensive therapy until further evidence is available.